Francesca Bonechi

Francesca Bonechi

Auto-generated profile, based on publicly available information

Francesca Bonechi

Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 September 2025 in Science Advances
Verified
Journal Article
Open access
XHXimena Hildebrandt
Ximena Hildebrandt
ÖVÖnay Veli
Önay Veli
AHArmel Hyoubi
Armel Hyoubi
JZJulia Zinngrebe
Julia Zinngrebe
AAAli T. Abdallah
Ali T. Abdallah
NPNIeves Peltzer
NIeves Peltzer
Adipocyte hypertrophy during obesity triggers chronic inflammation, leading to metabolic disorders. However, the role of adipocyte-specific inflammatory signaling in metabolic syndrome remains unclear. The linear ubiquitin chain assembly complex, LUBAC, is an E3-ligase that generates nondegradative linear ubiquitination (Lin-Ub). LUBAC regulates NF-κB/MAPK-driven inflammation and prevents cell death triggered by immune receptors like TNF receptor-1. Here, we show that mice lacking HOIP, the Lin-E3 ligase catalytic subunit of LUBAC, in adipocytes ( Hoip A-KO ) display lipodystrophy and heightened susceptibility to obesity-induced metabolic syndrome, particularly metabolic dysfunction-associated steatotic liver disease (MASLD). Mechanistically, loss of HOIP attenuates TNF-induced NF-κB activation and promotes cell death in human adipocytes. Inhibiting caspase-8–mediated cell death is sufficient to prevent lipodystrophy and MASLD in Hoip A-KO obese mice. HOIP expression in adipose tissue positively correlates with metabolic fitness in obese individuals. Overall, our findings reveal a fundamental developmental role for Lin-Ub in adipocytes by mitigating cell death–driven adipose tissue inflammation and protecting against obesity-related metabolic syndrome.

7 November 2025 in Cancer Research
Verified
Journal Article
Closed access
FBFrancesca Bonechi
Francesca Bonechi
MBMarina Bacci
Marina Bacci
NLNicla Lorito
Nicla Lorito
ASAlfredo Smiriglia
Alfredo Smiriglia
ASAngela Subbiani
Angela Subbiani
Andrea MorandiAndrea Morandi
Andrea Morandi
Endocrine therapy (ET) is the standard of care for estrogen receptor (ER)–positive breast cancer. Point mutations in the ligand-binding domain of the gene encoding the estrogen receptor (ESR1) are rare in naïve ER+ breast cancer while becoming common in the ET-resistant setting. In this study, we found that ESR1 mutations expose breast cancers to critical vulnerabilities related to lipid metabolism. Particularly, ESR1 mutations that induce constitutive ER activation drove aberrant lipid biogenesis and lipid upload in parallel with increased expression of acyl-CoA synthetase long-chain family member 4 (ACSL4), which plays a crucial role in fatty acid activation and has been shown to correlate with increased ferroptosis susceptibility. Although ER+ breast cancer cells displayed ferroptosis resistance, the presence of ESR1 mutations rendered tumor cells sensitive to ferroptosis induction. Importantly, ferroptosis inducers potentiated the effects of the selective ER degraders fulvestrant and elacestrant, which are the standard of care for breast cancers carrying ESR1 mutations. These findings, validated both in preclinical models and in patient-derived material, identify a combinatory therapeutic approach in the setting of ET resistance and establish ACSL4 as an important biomarker to recognize ER+ breast cancers susceptible to ferroptosis induction. Significance: ESR1 mutations in breast cancer induce metabolic changes that trigger ferroptosis sensitivity, enabling ferroptosis inducers to enhance selective ER degraders' efficacy and positioning ACSL4 as a biomarker for guiding therapy in endocrine-resistant disease.

2 February 2026
Verified
Other
Open access
FBFrancesca Bonechi
Francesca Bonechi
MBMarina Bacci
Marina Bacci
NLNicla Lorito
Nicla Lorito
ASAlfredo Smiriglia
Alfredo Smiriglia
ASAngela Subbiani
Angela Subbiani
Andrea MorandiAndrea Morandi
Andrea Morandi
Integrative functional analysis complementary to that described in the main Figure 2, showing that ACSL4 targeting prevents ferroptosis execution in MCF7-LTED Y537C cells

2 February 2026
Verified
Other
Open access
FBFrancesca Bonechi
Francesca Bonechi
MBMarina Bacci
Marina Bacci
NLNicla Lorito
Nicla Lorito
ASAlfredo Smiriglia
Alfredo Smiriglia
ASAngela Subbiani
Angela Subbiani
Andrea MorandiAndrea Morandi
Andrea Morandi
Endocrine therapy (ET) is the standard of care for estrogen receptor (ER)–positive breast cancer. Point mutations in the ligand-binding domain of the gene encoding the estrogen receptor (ESR1) are rare in naïve ER+ breast cancer while becoming common in the ET-resistant setting. In this study, we found that ESR1 mutations expose breast cancers to critical vulnerabilities related to lipid metabolism. Particularly, ESR1 mutations that induce constitutive ER activation drove aberrant lipid biogenesis and lipid upload in parallel with increased expression of acyl-CoA synthetase long-chain family member 4 (ACSL4), which plays a crucial role in fatty acid activation and has been shown to correlate with increased ferroptosis susceptibility. Although ER+ breast cancer cells displayed ferroptosis resistance, the presence of ESR1 mutations rendered tumor cells sensitive to ferroptosis induction. Importantly, ferroptosis inducers potentiated the effects of the selective ER degraders fulvestrant and elacestrant, which are the standard of care for breast cancers carrying ESR1 mutations. These findings, validated both in preclinical models and in patient-derived material, identify a combinatory therapeutic approach in the setting of ET resistance and establish ACSL4 as an important biomarker to recognize ER+ breast cancers susceptible to ferroptosis induction.Significance:ESR1 mutations in breast cancer induce metabolic changes that trigger ferroptosis sensitivity, enabling ferroptosis inducers to enhance selective ER degraders' efficacy and positioning ACSL4 as a biomarker for guiding therapy in endocrine-resistant disease.

2 February 2026
Verified
Other
Open access
FBFrancesca Bonechi
Francesca Bonechi
MBMarina Bacci
Marina Bacci
NLNicla Lorito
Nicla Lorito
ASAlfredo Smiriglia
Alfredo Smiriglia
ASAngela Subbiani
Angela Subbiani
Andrea MorandiAndrea Morandi
Andrea Morandi
Integrative functional analysis complementary to that described in the main Figure 3, showing that ACSL4 targeting prevents ferroptosis execution in MCF7 Y537C and T47D Y537C cells

2 February 2026
Verified
Other
Open access
FBFrancesca Bonechi
Francesca Bonechi
MBMarina Bacci
Marina Bacci
NLNicla Lorito
Nicla Lorito
ASAlfredo Smiriglia
Alfredo Smiriglia
ASAngela Subbiani
Angela Subbiani
Andrea MorandiAndrea Morandi
Andrea Morandi
ChIP-seq data relative to ESR1-mutant and its neomorphic transcriptional activity in regulating ACSL4, a feature linked to transcriptional reprogramming associated with ferroptosis